Artificial intelligence (AI) is transforming various industries as a major investing theme in 2025. The technology's ability ...

Biotech stock Halozyme Therapeutics is climbing back in constructive form from a severe drop in November. Shares got a boost after the drug-delivery developer reiterated its 2024 forecast and raised ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...

Analysts at HC Wainwright increased their FY2024 earnings per share estimates for shares of Evaxion Biotech A/S in a note issued to investors on Monday, February 3rd. HC Wainwright analyst S.

Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Viking Therapeutics stock plunged early Thursday on an earnings report that included mostly incremental updates for its weight-loss drugs.

Learn more about whether Catalyst Pharmaceuticals, Inc. or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's ...

Shares of uniQure (NASDAQ:QURE – Get Free Report) have received a consensus rating of “Buy” from the ten ratings firms that ...

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...